Clinical Trial Update: Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the effectiveness of the probiotic Escherichia coli M17 in treating Irritable bowel syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Escherichia coli M17 (Escherichia coli M17)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Irritable Bowel Syndrome (IBS) | Phase 2 | Status: COMPLETED